Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- HEI +2.4%
Other news:
- ALDX +17.2% (Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis)
- PTGX +6.2% (Point72 increased passive stake to 5.5%)
- KVUE +5.0% (favorable court ruling in Tylenol case)
- KRYS +4.5% (Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC))
- TSE +3.8% (Director bought 50,000 shares at $7.03 - $7.40 worth ~$361K)
- DNA +3.2% (subsidiary, FGen AG, awarded funding through the European Innovation Council's Pathfinder Challenge program for sustainable milk protein production project)
- DADA +3.0% (Mr. Lijun Xin will step down as the Chairman of the Board and a member of the nominating and corporate governance committee of the Board; Beck Zhaoming Chen resigns as CFO and Board named Henry Jun Mao to succeed)
- CHDN +2.3% ( announces repurchase of one million shares for $123.75/share)
- XOMA +2.0% (entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 mln of capital with certain funds managed by the credit platform of Blue Owl Capital Inc.)
- FMC +1.8% (initiates global restructuring plan dubbed "Project Focus"; launches voluntary separation program in select jurisdictions and workforce reduction actions in Brazil business)
- HQI +1.9% (Director bought 6,000 shares at $16.18 - $16.31 worth ~$97K)
- AU +1.6% (to make a strategic investment in G2 Goldfields Inc.)
- CHWY +1.6% (Director bought 12,242 shares at $20.13-$20.67 worth ~$250K)
- CD +1.3% (announces completion of going private transaction)
- MRTX +1.2% (Mirati Therapeutics / Bristol-Myers Squibb (BMY) required waiting period under the HSR Act with respect to the Merger expired at 11:59 p.m. Eastern time on December 18, 2023)
Analyst comments:
- WVE +7.6% (upgraded to Outperform from Market Perform at Leerink Partners; tgt raised to $12)
- ARVN +5.8% (upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $63)
- ACAD +4.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $40)
- FOLD +4.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $20)
- NOVA +5.3% (upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $26)
- RUN +4.2% (upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $31)
- RYTM +3.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $55)
- CHWY +3.3% (initiated with a Buy at Jefferies; tgt $27)
- AMGN +1.5% (upgraded to Outperform from Market Perform at BMO Capital Markets; tgt raised to $326)
- AIG +1.4% (upgraded to Outperform from Market Perform at BMO Capital Markets; tgt raised to $83)
- ITRI +1.4% ( upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $91)
- ROK +1.4% (upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $357)